Objectives
The purpose of this study is to analyze the influence of the corporate governance of pharmaceutical companies on research and development (R&D) investment. Methods
The period of the empirical analysis is from 2000 to 2012. Financial statements and comments in general, and internal transactions were extracted from TS-2000 of the Korea Listed Company Association. Sample firms were those that belong to the medical substance and drug manufacturing industries. Ultimately, 786 firm-year data of 81 firms were included in the sample (unbalanced panel data). Results
The shareholding ratio of major shareholders and foreigners turned out to have a statistically significant influence on R&D investment (p < 0.05). No statistical significance was found in the shareholding ratio of institutional investors and the ratio of outside directors. Conclusion
The higher the shareholding ratio of the major shareholders, the greater the R&D investment. There will be a need to establish (or switch to) a holding company structure. Holding companies can directly manage R&D in fields with high initial risks, and they can diversify these risks. The larger the number of foreign investors, the greater the R&D investment, indicating that foreigners directly or indirectly impose pressure on a manager to make R&D investments that bring long-term benefits.
Citations
Citations to this article as recorded by
EFFECT OF CORPORATE GOVERNANCE PRACTICES ON R&D AND INNOVATION COSTS: A CASE STUDY ON BORSA İSTANBUL Hüseyin Ali KUTLU, Bekir GEREKAN Muhasebe ve Vergi Uygulamaları Dergisi.2021; 14(3): 967. CrossRef
Corporate governance and the environment in the health sector: Systematic literature review Isabel Cristina Panziera Marques, Zélia Maria da Silva Serrasqueiro Teixeira, Fernanda Maria Duarte Nogueira Journal of Governance and Regulation.2020; 9(2): 8. CrossRef
Gouvernance et intensité d’innovation dans les ETI innovantes Léopold Djoutsa Wamba, Éric Braune, Frédéric Teulon Management & Avenir.2020; N° 118(4): 111. CrossRef
Differentiation of innovation strategies based on pharmaceutical licensing agreements: Insight from Korean pharmaceutical firms Chie Hoon Song, Jens Leker Technology Analysis & Strategic Management.2019; 31(2): 169. CrossRef